Cooperative Agreement UG3DA063357
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$4.7M
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Cooperative Agreement
Place of Performance
Pennsylvania, USA
Similar Awards
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $19,302,777 to Nirsum Laboratories, Inc. to accelerate the development of NRS-033, a long-acting injectable medication for opioid use disorder (OUD). The key products and services to be delivered under this award include late-stage chemistry, manufacturing, and controls (CMC) for the active pharmaceutical ingredient (API) and drug...
The National Institute on Drug Abuse (NIDA), through the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $23,579,701 Cooperative Agreement to Ensysce Biosciences, Inc. to continue the clinical development of PF614-MPAR, an opioid product with overdose protection. PF614-MPAR is a combination product that includes a trypsin-activated abuse-resistant oxycodone prodrug (PF614) and the trypsin inhibitor nafamostat, which provides overdose protection. The goal of this award is to...
This Project Grant award of $398,137 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop high-precision epigenetic therapeutics for opioid use disorder (OUD). The grantee, Boston Interactome LLC, will apply a mammalian cell-based compound screening platform to identify functional modulators of the neuronal G9A complex, which regulates DFosB expression under chronic opioid exposure. The efficacy and specificity of the...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding the development of a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). The grantee, Epivario Inc., a for-profit biotechnology research organization, will screen a new class of ACSS2 inhibitors and evaluate their efficacy in preclinical animal models of OUD. Specifically, the $275,253 award will support...
The National Institute on Drug Abuse (NIDA) awarded a $11,872,077 Cooperative Agreement (CFDA 93.279 - Drug Use and Addiction Research Programs) to Sparian Biosciences Inc. (doing business as Palion Therapeutics) to develop SBS-226, a novel chemical entity that acts as a mu-opioid receptor agonist and delta-opioid receptor antagonist, for the treatment of opioid use disorder (OUD). The project aims to advance SBS-226 through IND-enabling studies and a Phase 1 clinical trial. Sparian...
The National Institute on Drug Abuse (NIDA) awarded a $1,539,426 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to Serodopa Therapeutics Inc. to develop a novel intranasal formulation of a naloxone derivative for the reversal of opioid-induced respiratory depression caused by high-potency opioids such as fentanyl. The project aims to complete formulation development, preclinical toxicology and safety testing required to prepare an Investigational New Drug (IND)...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is for a $1,837,542 project titled "Targeting Treatment-Resistant OUD with Ketamine-Assisted Mindfulness-Oriented Recovery Enhancement." The project aims to investigate the safety, preliminary efficacy, and psycho-physiological mechanisms of combining the psychotherapy Mindfulness-Oriented Recovery Enhancement (MORE) with ketamine...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $11,811,988 in funding to The University of Texas Health Science Center at San Antonio (UTHSCSA) to continue development of the novel mu-opioid receptor antagonist Methocinnamox (MCAM) for preventing opioid relapse after detoxification. The 3-year project aims to: 1) submit an Investigational New Drug (IND) application for MCAM to prevent...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), supports research to identify and validate G protein-coupled receptors (GPCRs) expressed by somatostatin-expressing inhibitory neurons in the prefrontal cortex as potential targets for developing new treatments for opioid use disorder. The $1,717,200 award, spanning August 1, 2024 to May 31, 2029, will enable researchers at the University of...
This Project Grant award of $399,536 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research by Chemregen Inc. to design, synthesize, and test non-opioid drug candidates as a new approach to combat the opioid crisis. The key objectives are to: 1) Design and synthesize lead and control compounds, characterize them chemically and pharmacologically for receptor binding, and conduct ADMET studies; and 2) Characterize human...